Advertisement

Solid Lipid Nanoparticles: A Multidimensional Drug Delivery System

  • Abhishek Pandey
Chapter
Part of the Environmental Chemistry for a Sustainable World book series (ECSW, volume 39)

Abstract

The development of drug delivery carriers is often very challenging, due to the physicochemical properties of the drug such as poor solubility, low permeability, and short half-life. Development of colloidal delivery systems has introduced new avenues for safe and effective drug delivery. However, the absence of large-scale production methods, toxic solvent residuals, limited stability, and cytotoxicity of some polymeric particles are the major issues associated with colloidal carriers. On this note, the concept of lipid-based nanoparticles like solid lipid nanoparticles matured. Solid lipid nanoparticles not only combine the advantages of the conventional drug delivery systems but also bypass their major disadvantages.

Solid lipid nanoparticles represent an alternative carrier system to conventional colloidal carriers due to their specific features such as use of natural fabrication components, size and related narrow distribution, enhanced stability, and increased permeation through biological barriers. Additionally, increased solubility, biocompatibility, ease of manufacture, and different possible administration routes enable solid lipid nanoparticles a frontline drug delivery system. Here, I reviewed up-to-date developments about solid lipid nanoparticles as a potential nanocolloidal system for drug delivery. The major points are as follows: (1) overview of the different production methods, which are suitable for large-scale production, and analytical techniques used for characterization of solid lipid nanoparticles are described; (2) in vitro evaluation, pharmacokinetics, and tissue distribution of solid lipid nanoparticles; and (3) stability, toxicity, and status of excipients used in the fabrication of solid lipid nanoparticles have been discussed in this chapter. This chapter selectively highlights major therapeutic applications of solid lipid nanoparticles in drug delivery along with mechanism of action of the incorporated drug molecule.

Keywords

Solid lipid nanoparticles Pharmacokinetics Novel drug delivery system Colloidal drug carrier Bioavailability Biological barrier Anticancer Antitumor Vaccine adjuvants 

References

  1. Akanda MH, Rai R, Slipper IJ, Chowdhry BZ, Lamprou D, Getti G, Douroumis D (2015) Delivery of retinoic acid to LNCap human prostate cancer cells using solid lipid nanoparticles. Int J Pharm 493:161–171.  https://doi.org/10.1016/j.ijpharm.2015.07.042CrossRefPubMedGoogle Scholar
  2. Almeida AJ, Runge S, Müller RH (1997) Peptide-loaded solid lipid nanoparticles (SLN): influence of production parameters. Int J Pharm 149:255–265.  https://doi.org/10.1016/S0378-5173(97)04885-0CrossRefGoogle Scholar
  3. Almeida AJ, Souto E (2007) Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 59:478–490.  https://doi.org/10.1016/j.addr.2007.04.007CrossRefPubMedGoogle Scholar
  4. Ansari MJ, Anwer K, Jamil S, Al-Shdefat R, Ali BE, Ahmad MM, Ansari MN (2016) Enhanced oral bioavailability of insulin-loaded solid lipid nanoparticles: pharmacokinetic bioavailability of insulin-loaded solid lipid nanoparticles in diabetic rats. Drug Deliv 23:1972–1979.  https://doi.org/10.3109/10717544.2015.1039666CrossRefPubMedGoogle Scholar
  5. Baek JS, Cho CW (2013) 2-Hydroxypropyl-β-cyclodextrin-modified solid lipid nanoparticles of paclitaxel for overcoming p-glycoprotein function in multidrug-resistant breast cancer cells. J Pharm Pharmacol 65:72–78.  https://doi.org/10.1111/j.2042-7158.2012.01578.xCrossRefPubMedGoogle Scholar
  6. Ball RL, Bajaj P, Whitehead KA (2018) Oral delivery of siRNA lipid nanoparticles: fate in the GI tract. Sci Rep 8:2178.  https://doi.org/10.1038/s41598-018-20632-6CrossRefPubMedPubMedCentralGoogle Scholar
  7. Bargoni A, Cavalli R, Zara GP, Fundarò A, Caputo O, Gasco MR (2001) Transmucosal transport of tobramycin incorporated in solid lipid nanoparticles (solid lipid nanoparticles) after duodenal administration to rats. Part II–tissue distribution. Pharmacol Res 43:497–502.  https://doi.org/10.1006/phrs.2001.0813CrossRefPubMedGoogle Scholar
  8. Battaglia L, Serpe L, Muntoni E, Zara G, Trotta M, Gallarate M (2011) Methotrexate-loaded solid lipid nanoparticles prepared by coacervation technique: in vitro cytotoxicity and in vivo pharmacokinetics and biodistribution. Nanomedicine 6:1561–1573.  https://doi.org/10.2217/nnm.11.52CrossRefPubMedGoogle Scholar
  9. Bhandari R, Kaur IP (2013) Pharmacokinetics, tissue distribution and relative bioavailability of isoniazid-solid lipid nanoparticles. Int J Pharm 30:202–212.  https://doi.org/10.1016/j.ijpharm.2012.11.042CrossRefGoogle Scholar
  10. Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C (2007) Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev 59:454–477.  https://doi.org/10.1016/j.addr.2007.04.011CrossRefPubMedGoogle Scholar
  11. Bocca C, Caputo O, Cavalli R, Gabriel L, Miglietta A, Gasco MR (1998) Phagocytic uptake of fluorescent stealth and non-stealth solid lipid nanoparticles. Int J Pharm 175:185–193.  https://doi.org/10.1016/S0378-5173(98)00282-8CrossRefGoogle Scholar
  12. Cai S, Yang Q, Bagby TR, Forrest ML (2011) Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. Adv Drug Deliv Rev 63:901–908.  https://doi.org/10.1016/j.addr.2011.05.017CrossRefPubMedPubMedCentralGoogle Scholar
  13. Cavalli R, Morel S, Gasco MR, Saettone MF, Chetoni P (1995) Preparation and evaluation in vitro of colloidal lipospheres containing pilocarpine as ion-pair. Int J Pharm 117:243–246.  https://doi.org/10.1016/0378-5173(94)00339-7CrossRefGoogle Scholar
  14. Cavalli R, Bocca C, Miglietta A, Caputo O, Gasco MR (1999) Albumin adsorption on stealth and non-stealth solid lipid nanoparticles. STP Pharma Sci 9:183–189. http://hdl.handle.net/2318/126138Google Scholar
  15. Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF (2002a) Solid lipid nanoparticles as ocular delivery systems for tobramycin. Int J Pharm 238:241–245.  https://doi.org/10.1016/S0378-5173(02)00080-7CrossRefPubMedGoogle Scholar
  16. Cavalli R, Zara GP, Ugazio E, Muntoni E, Serpe L, Gasco MR (2002b) Paclitaxel incorporated in solid lipid nanoparticles (solid lipid nanoparticles): preliminary pharmacokinetic study and brain concentration. In: Proceedings of the 4th world meet ADRITELF/APGI/APV, pp 669–670Google Scholar
  17. Chuang CH, Wu PC, Tsai TH, Fang YP, Tsai YH, Cheng TC, Huang CC, Huang MY, Chen FM, Hsieh YC, Lin WW, Tsai MJ, Cheng TL (2017) Development of pH-sensitive cationic PEGylated solid lipid nanoparticles for selective cancer-targeted therapy. J Biomed Nanotechnol 13:192–203.  https://doi.org/10.1016/j.nbd.2010.03.022CrossRefPubMedGoogle Scholar
  18. Das S, Ng WK, Kanaujia P, Kim S, Tan RB (2011) Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables. Colloids Surf B Biointerfaces 1:483–489.  https://doi.org/10.1016/j.colsurfb.2011.07.036CrossRefGoogle Scholar
  19. Date AA, Naik B, Nagarsenker MS (2006) Novel drug delivery systems: potential in improving topical delivery of antiacne agents. Skin Pharmacol Physiol 19:2–16.  https://doi.org/10.1159/000089138CrossRefPubMedGoogle Scholar
  20. De Souza AL, Andreani T, de Oliveira RN, Kiill CP, dos Santos FK, Allegretti SM, Chaud MV, Souto EB, Silva AM, Gremião MP (2014) In vitro evaluation of permeation, toxicity and effect of praziquantel-loaded solid lipid nanoparticles against Schistosoma mansoni as a strategy to improve efficacy of the schistosomiasis treatment. Int J Pharm 10:31–37.  https://doi.org/10.1016/j.ijpharm.2013.12.022CrossRefGoogle Scholar
  21. Demirel M, Yazan Y, Müller RH, Kiliç F, Bozan B (2001) Formulation and in vitro-in vivo evaluation of piribedil solid lipid micro and nanoparticles. J Microencapsul 18:359–371.  https://doi.org/10.1080/02652040010018119CrossRefPubMedGoogle Scholar
  22. Dhawan S, Kapil R, Singh B (2010) Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery. J Pharm Pharmacol 63:342–351.  https://doi.org/10.1111/j.2042-7158.2010.01225.xCrossRefGoogle Scholar
  23. Ding Y, Qiao A, Fan GH (2010) Indirubin-3′-monoxime rescues spatial memory deficits and attenuates beta-amyloid-associated neuropathology in a mouse model of Alzheimer’s disease. Neurobiol Dis 39:156–168.  https://doi.org/10.1016/j.nbd.2010.03.022CrossRefPubMedGoogle Scholar
  24. Dingler A, Blum RP, Niehus RH, Gohla S (1999) Solid lipid nanoparticles (solid lipid nanoparticles/lipopearls)-a pharmaceutical and cosmetic carrier for the application of vitamin E in dermal products. J Microencapsul 16:751–767.  https://doi.org/10.1080/026520499288690CrossRefPubMedGoogle Scholar
  25. Doktorovová S, Santos DL, Costa I, Andreani T, Souto ES, Silva AM (2014) Cationic solid lipid nanoparticles interfere with the activity of antioxidant enzymes in hepatocellular carcinoma cells. Int J Pharm 47:18–27CrossRefGoogle Scholar
  26. Dwivedi P, Khatik R, Khandelwal K, Taneja I, Raju KS, Wahajuddin, Paliwal SK, Dwivedi AK, Mishra PR (2014) Pharmacokinetics study of arteether loaded solid lipid nanoparticles: an improved oral bioavailability in rats. Int J Pharm 466(1–2):321–327CrossRefGoogle Scholar
  27. Eldridge JH, Hammond CJ, Meulbroek JA (1990) Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer’s patches. J Control Release 11:205–214.  https://doi.org/10.1016/0168-3659(90)90133-ECrossRefGoogle Scholar
  28. El-Housiny, Maii Y, Eldeen AS (2018) Fluconazole- loaded solid lipid nanoparticles topical gel for treatment of pityriasis versicolor: formulation and clinical study. Drug Deliv 25:78–90.  https://doi.org/10.1080/10717544.2017.1413444CrossRefPubMedGoogle Scholar
  29. El-Say KM, Hosny KM (2018) Optimization of carvedilol solid lipid nanoparticles: an approach to control the release and enhance the oral bioavailability on rabbits. PLoS One 13:e0203405.  https://doi.org/10.1371/journal.pone.0203405CrossRefPubMedPubMedCentralGoogle Scholar
  30. Emami J, Mohiti H, Hamishehkar H, Varshosaz J (2015) Formulation and optimization of solid lipid nanoparticle formulation for pulmonary delivery of budesonide using Taguchi and Box-Behnken design. Res Pharm Sci 10:17–33PubMedPubMedCentralGoogle Scholar
  31. Esposito E, Fantin M, Marti M, Drechsler M, Paccamiccio L, Mariani P, Sivieri E, Lain F, Menegatti E, Morari M, Cortesi R (2008) Solid lipid nanoparticles as delivery systems for bromocriptine. Pharm Res 25:1521–1530.  https://doi.org/10.1007/s11095-007-9514-yCrossRefPubMedGoogle Scholar
  32. Erni C, Suard C, Freitas S, Dreher D, Merkle HP, Walter E (2002) Evaluation of cationic solid lipid microparticles as synthetic carriers for the targeted delivery of macromolecules to phagocytic antigen-presenting cells. Biomaterials 23:4667–4676.  https://doi.org/10.1016/s0142-9612(02)00216–8CrossRefPubMedGoogle Scholar
  33. Fatouh AM, Elshafeey AH, Abdelbary A (2017) Intranasal agomelatine solid lipid nanoparticles to enhance brain delivery: formulation, optimization and in vivo pharmacokinetics. Drug Des Devel Ther 11:1815–1825.  https://doi.org/10.2147/DDDT.S102500CrossRefPubMedPubMedCentralGoogle Scholar
  34. Freitas C, Muller RH (1998) Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle dispersions. Int J Pharm 168:221–299.  https://doi.org/10.1016/S0378-5173(98)00092-1CrossRefGoogle Scholar
  35. Freitas C, Muller RH (1999a) Correlation between long-term stability of solid lipid nanoparticles and crystallinity of the lipid phase. Eur J Pharm Biopharm 47:125–132.  https://doi.org/10.1016/S0939-6411(98)00074-5CrossRefPubMedGoogle Scholar
  36. Freitas C, Muller RH (1999b) Stability determination of solid lipid nanoparticles in aqueous dispersion after addition of electrolyte. J Microencapsul 16:59–71.  https://doi.org/10.1080/026520499289310CrossRefPubMedGoogle Scholar
  37. Fundaro A, Cavalli R, Bargoni A, Vighetto D, Zara GP, Gasco MR (2000) Non stealth and stealth solid lipid nanoparticles carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol Res 42:337–343.  https://doi.org/10.1006/phrs.2000.0695CrossRefPubMedGoogle Scholar
  38. Garcia-Fuentes M, Torres D, Alonso MJ (2002) Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Colloids Surf B Biointerfaces 27:159–168.  https://doi.org/10.1016/S0927-7765(02)00053-XCrossRefGoogle Scholar
  39. Gaspar DP, Gaspar MM, Eleutério CV, Grenha A, Blanco M, Gonçalves LMD, Taboada P, Almeida AJ, Remuñán-López C (2017) Microencapsulated solid lipid nanoparticles as a hybrid platform for pulmonary antibiotic delivery. Mol Pharm 14:2977–2990.  https://doi.org/10.1021/acs.molpharmaceut.7b00169CrossRefPubMedGoogle Scholar
  40. Gastaldi L, Battaglia L, Peira E, Chirio D, Muntoni E, Solazzi I, Gallarate M, Dosio F (2014) Solid lipid nanoparticles as vehicles of drugs to the brain: current state of the art. Eur J Pharm Biopharm 87:433–444.  https://doi.org/10.1016/j.ejpb.2014.05.004CrossRefPubMedGoogle Scholar
  41. Geszke-Moritz M, Moritz M (2016) Solid lipid nanoparticles as attractive drug vehicles: composition, properties and therapeutic strategies. Mater Sci Eng C Mater Biol Appl 68:982–994.  https://doi.org/10.1016/j.ejpb.2014.05.00410.1016/j.msec.2016.05.119CrossRefPubMedGoogle Scholar
  42. Gieseler F, Rudolph P, Kloeppel G, Foelsch UR (2003) Resistance mechanisms of gastrointestinal cancers: why does conventional chemotherapy fail? Int J Color Dis 470.  https://doi.org/10.1007/s00384-003-0496-xl
  43. Girotra P, Singh SK (2017) Multivariate optimization of rizatriptan benzoate-loaded solid lipid nanoparticles for brain targeting and migraine management. AAPS Pharm Sci Tech 18:517–528.  https://doi.org/10.1208/s12249-016-0532-0CrossRefGoogle Scholar
  44. Gonçalez ML, Rigon RB, Pereira-da-Silva MA, Chorilli M (2017) Curcumin-loaded cationic solid lipid nanoparticles as a potential platform for the treatment of skin disorders. Pharmazie 1:721–727.  https://doi.org/10.1691/ph.2017.7101CrossRefGoogle Scholar
  45. Gualbert J, Shahgaldian P, Coleman AW (2003) Interactions of amphiphilic calyx [4] arene-based solid lipid nanoparticles with bovine serum albumin. Int J Pharm 257:69–73.  https://doi.org/10.1016/S0378-5173(03)00138-8CrossRefPubMedGoogle Scholar
  46. Gupta S, Kesarla R, Chotai N, Misra A, Omri A (2017) Systematic approach for the formulation and optimization of solid lipid nanoparticles of Efavirenz by high pressure homogenization using design of experiments for brain targeting and enhanced bioavailability. Biomed Res Int 1–18.  https://doi.org/10.1155/2017/5984014Google Scholar
  47. Hajipour H, Hamishehkar H, Rahmati-yamchi M, Shanehbandi D, Nazari Soltan Ahmad S (2018) Enhanced anti-cancer capability of ellagic acid using solid lipid nanoparticles. Int J Cancer Manag 11:9402.  https://doi.org/10.5812/ijcm.9402CrossRefGoogle Scholar
  48. Hansraj GP, Singh SK, Kumar P (2015) Sumatriptan succinate loaded chitosan solid lipid nanoparticles for enhanced antimigraine potential. Int J Biol:467–476.  https://doi.org/10.1016/j.ijbiomac.2015.08.035CrossRefGoogle Scholar
  49. Haque S, Md S, Sahni JK, Ali J, Baboota S (2014) Development and evaluation of brain targeted intranasal alginate nanoparticles for treatment of depression. J Psychiatr Res 48:1–12.  https://doi.org/10.1016/j.jpsychires.2013.10.011CrossRefPubMedGoogle Scholar
  50. Harivardhan Reddy L, Sharma RK, Chuttani K, Mishra AK, Murthy RS (2005) Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton’s lymphoma tumor bearing mice. J Control Release 105:185–198.  https://doi.org/10.1208/aapsj080229CrossRefPubMedGoogle Scholar
  51. Hommoss A, Müller RH (2006) Release of perfumes: modulation by type of matrix lipid in NLC. In: Proceeding in the 5th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, GenevaGoogle Scholar
  52. Hwang TL, Aljuffali IA, Hung CF, Chen CH, Fang JY (2015) The impact of cationic solid lipid nanoparticles on human neutrophil extracellular traps (NETs). Chem Biol Interact 235:108–114.  https://doi.org/10.1016/j.cbi.2015.04.011CrossRefGoogle Scholar
  53. Ibrahim WM, Al Omrani AH, Yassin AE (2014) Novel sulpiride-loaded solid lipid nanoparticles with enhanced intestinal permeability. Int J Nanomedicine 9:129–144.  https://doi.org/10.2147/IJN.S54413CrossRefPubMedGoogle Scholar
  54. Jang DJ, Moon C, Oh E (2016) Improved tumor targeting and antitumor activity of camptothecin loaded solid lipid nanoparticles by preinjection of blank solid lipid nanoparticles. Biomed Pharmacother 80:162–172.  https://doi.org/10.1016/j.biopha.2016.03.018CrossRefPubMedGoogle Scholar
  55. Jenning V, Gysler A, Schafer-Korting M, Gohla S (2000a) Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and targeting to the upper skin. Eur J Pharm Biopharm 49:211–218.  https://doi.org/10.1016/S0939-6411(99)00075-2CrossRefPubMedGoogle Scholar
  56. Jenning V, Schafer-Korting M, Gohla S (2000b) Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. J Control Release 66:115–126.  https://doi.org/10.1016/S0168-3659(99)00223-0CrossRefPubMedGoogle Scholar
  57. Jia L, Zheng JJ, Jiang SM, Huang KH (2010) Preparation, physicochemical characterization and cytotoxicity in vitro of gemcitabine loaded PEG-PDLLA nano vesicles. World J Gastroenterol 16:1008–1013.  https://doi.org/10.3748/wjg.v16.i8.1008CrossRefPubMedPubMedCentralGoogle Scholar
  58. Joshi MD, Müller RH (2009) Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm 71:161–172.  https://doi.org/10.1016/j.ejpb.2008.09.003CrossRefGoogle Scholar
  59. Joshi AS, Patel HS, Belgamwar VS (2012) Solid lipid nanoparticles of ondansetron HCl for intranasal delivery: development, optimization and evaluation. J Mater Sci Mater 23:2163–2175.  https://doi.org/10.1007/s10856-012-4702-7CrossRefGoogle Scholar
  60. Kakkar V, Singh S, Singla D, Kaur IP (2011) Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin. Mol Nutr Food Res 55:495–503.  https://doi.org/10.1002/mnfr.201000310CrossRefPubMedGoogle Scholar
  61. Kelidari HR, Saeedi M, Akbari J, Morteza-Semnani K, Gill P, Valizadeh H, Nokhodchi A (2015) Formulation optimization and in vitro skin penetration of spironolactone loaded solid lipid nanoparticles. Colloids Surf B Biointerfaces 128:473–479.  https://doi.org/10.1016/j.colsurfb.2015.02.046CrossRefPubMedGoogle Scholar
  62. Kheradmandnia S, Vasheghani-Farahani E, Nosrati M, Atyabi F (2010) Preparation and characterization of ketoprofen-loaded solid lipid nanoparticles made from beeswax and carnauba. Nanomedicine 6:753–910.  https://doi.org/10.1016/j.nano.2010.06.003CrossRefPubMedGoogle Scholar
  63. Kumar M, Kakkar V, Mishra AK, Chuttani K, Kaur IP (2014) Intranasal delivery of streptomycin sulfate (STRS) loaded solid lipid nanoparticles to brain and blood. Int J Pharm:223–233.  https://doi.org/10.1016/j.ijpharm.2013.11.038CrossRefGoogle Scholar
  64. Kuo YC, Ko HF (2013) Targeting delivery of saquinavir to the brain using 83-14 monoclonal antibody-grafted solid lipid nanoparticles. Biomaterials 34:4818–4830.  https://doi.org/10.1016/j.biomaterials.2013.03.013CrossRefPubMedGoogle Scholar
  65. Labovkina T, Jacobson GB, Gonzalez-Gonzalez E, Hickerson RP, Leake D, Kaspar RL, Contag CH, Zare RN (2011) In vivo sustained release of siRNA from solid lipid nanoparticles. ACS Nano 5:9977–9983.  https://doi.org/10.1021/nn203745nCrossRefGoogle Scholar
  66. Lestari LADM, Indrayanto G (2014) Curcumin. In: Brittain H (ed) Profiles of drug substances, excipients and related methodology, vol 39. Academic Press, Cambridge, pp 113–204.  https://doi.org/10.1016/B978-0-12-800173-8.00003-9CrossRefGoogle Scholar
  67. Li JM, Chen W, Wang H (2009) Preparation of albumin nanospheres loaded with gemcitabine and their cytotoxicity against BXPC-3 cells in vitro. Acta Pharmacol Sin 30:1337–1343.  https://doi.org/10.1038/aps.2009.125CrossRefPubMedPubMedCentralGoogle Scholar
  68. Lin CH, Chen CH, Lin ZC, Fang JY (2017) Recent advances in oral delivery of drugs and bioactive natural products using solid lipid nanoparticles as the carriers. J Food Drug Anal 2:219–234.  https://doi.org/10.1016/j.jfda.2017.02.001CrossRefGoogle Scholar
  69. Lippacher A, FluÈssig, halbfeste (2001) Solid lipid nanoparticles-Dispersionen zur topischen Applikation, Ph.D. thesis, Free University of BerlinGoogle Scholar
  70. Londhe V, Save S (2017) Zaltoprofen loaded solid lipid nanoparticles for topical delivery: formulation design, in vitro and ex vivo evaluation. MOJ Bioequiv Availab 4:248–254.  https://doi.org/10.15406/mojbb.2017.04.00065CrossRefGoogle Scholar
  71. Maaûen S, Schwarz C, Mehnert W, Lucks JS, Yunis-Specht F, MuÈller BW, MuÈller RH (1993) Comparison of cytotoxicity between polyester nanoparticles and solid lipid nanoparticles (solid lipid nanoparticles). Proc Int Symp Control Release Bioact Mater 20:490–491Google Scholar
  72. Madan J, Pandey RS, Jain V, Katare OM, Chandra R, Katyal A (2013) Poly(ethylene)-glycol conjugated solid lipid nanoparticles of noscapine improve biological half-life, brain delivery and efficacy in glioblastoma cells. Nanotechnol Biol Med 9:492–503.  https://doi.org/10.1016/j.nano.2012.10.003CrossRefGoogle Scholar
  73. Maia CS, Mehenert W, Schafer KM (2000) Solid lipid nanoparticles as drug carrier for topical glucocorticoids. Int J Pharm 196:165–167.  https://doi.org/10.1016/S0378-5173(99)00413-5CrossRefPubMedGoogle Scholar
  74. Makwana V, Jain R, Patel K, Nivsarkar M, Joshi A (2015) Solid lipid nanoparticles of Efavirenz as lymph targeting drug delivery system: elucidation of mechanism of uptake using chylomicron flow blocking approach. Int J Pharm 495:439–446.  https://doi.org/10.1016/j.ijpharm.2015.09.014CrossRefPubMedGoogle Scholar
  75. Manjunath K, Venkateswarlu V (2005) Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release 107:215–228.  https://doi.org/10.1016/j.jconrel.2005.06.006CrossRefPubMedGoogle Scholar
  76. Martins S, Tho I, Reimold I, Fricker G, Souto E, Ferreira D, Brandl M (2012) Brain delivery of camptothecin by means of solid lipid nanoparticles: formulation design, in vitro and in vivo studies. Int J Pharm 439:49–62.  https://doi.org/10.1016/j.ijpharm.2012.09.054CrossRefPubMedGoogle Scholar
  77. Martins SM, Sarmento B, Nunes C, Lúcio M, Reis S, Ferreira DC (2013) Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration. Eur J Pharm Biopharm 85:488–502.  https://doi.org/10.1016/j.ejpb.2013.08.011CrossRefPubMedGoogle Scholar
  78. Mehnert W, Mäder K (2001) Solid lipid nanoparticles production, characterization and applications. Adv Drug Deliv Rev 47:165–196.  https://doi.org/10.1016/S0169-409X(01)00105-3CrossRefPubMedGoogle Scholar
  79. Mendoza AE, Campanero MA, Iglesia-Vicente JD, Gajate C, Mollinedo F, Blanco-Prieto MJ (2009) Antitumor alkyl ether lipid edelfosine: tissue distribution and pharmacokinetic behavior in healthy and tumor-bearing immune suppressed mice. Clin Cancer Res 15:858–864.  https://doi.org/10.1158/1078-0432.CCR-08-1654CrossRefGoogle Scholar
  80. Minelli R, Serpe L, Pettazzoni P, Minero V, Barrera G, Gigliotti C, Mesturini R, Rosa AC, Gasco P, Vivenza N, Muntoni E, Fantozzi R, Dianzani U, Zara GP, Dianzani C (2012) Cholesteryl butyrate solid lipid nanoparticles inhibit the adhesion and migration of colon cancer cells. Br J Pharmacol 166:587–601.  https://doi.org/10.1111/j.1476-5381.2011.01768.xCrossRefPubMedPubMedCentralGoogle Scholar
  81. Mishra H, Mishra D, Mishra PK, Nahar M, Dubey V, Jain NK (2010) Evaluation of solid lipid nanoparticles as carriers for delivery of hepatitis B surface antigen for vaccination using subcutaneous route. J Pharm Sci 13:495–509.  https://doi.org/10.18433/J3XK53CrossRefGoogle Scholar
  82. Mishra V, Bansal KK, Verma A, Yadav N, Thakur S, Sudhakar K, Rosenholm JM (2018) Solid lipid nanoparticles: emerging colloidal nano drug delivery systems. Pharmaceutics 10:1–21.  https://doi.org/10.3390/pharmaceutics10040191CrossRefGoogle Scholar
  83. Morel S, Gasco MR, Cavalli R (1995) Incorporation in lipospheres of [d-Trp-6] LHRH. Int J Pharm 119:125–126.  https://doi.org/10.1016/0378-5173(94)90466-9CrossRefGoogle Scholar
  84. Morel S, Ugazio E, Cavalli R, Gasco MR (1996) Thymopentin in solid lipid nanoparticles. Int J Pharm 132:259–261.  https://doi.org/10.1016/0378-5173(95)04388-8CrossRefGoogle Scholar
  85. Müller RH, Dingler A (1998) The next generation after the liposomes: (SLNe, Lipopearls) solid lipid nanoparticles as dermal carrier in cosmetics. Eurocosmetics 7/8:19–26Google Scholar
  86. Muller RH, Schwarz C, Mehenert W (1994) Incorporation of lipophilic drugs and release profiles of solid lipid nanoparticles. Proc Int Symp Control Release Bioactive Mater 21:46–47Google Scholar
  87. Müller RH, Mehnert W, Lucks JS, Schwarz C, zur Mühlen A, Weyhers H, Freitas C, Rühl D (1995) Solid lipid nanoparticles (solid lipid nanoparticles)- an alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm 41:62–69Google Scholar
  88. Müller RH, Mäder K, Gohla S (2000) Solid lipid nanoparticles (solid lipid nanoparticles) for controlled drug delivery a review of the state of the art. Eur J Pharm Biopharm 50:161–177.  https://doi.org/10.1016/S0939-6411CrossRefPubMedGoogle Scholar
  89. Müller RH, Radtke M, Wissing SA (2002) Solid lipid nanoparticles and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 54:131–155.  https://doi.org/10.1016/S0169-409X(02)00118-7CrossRefGoogle Scholar
  90. Nafee N, Husari A, Maurer CK, Lu C, de Rossi C, Steinbach A, Hartmann RW, Lehr CM, Schneider M (2014) Antibiotic-free nano therapeutics: ultra small, mucus penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors. J Control Release 192:131–140.  https://doi.org/10.1016/j.jconrel.2014.06.055CrossRefPubMedGoogle Scholar
  91. Nandini PT, Doijad RC, Shivakumar HN, Dandagi PM (2015) Formulation and evaluation of gemcitabine-loaded solid lipid nanoparticles. Drug Deliv 22:647–651.  https://doi.org/10.3109/10717544.2013.860502CrossRefPubMedGoogle Scholar
  92. Negi JS, Chattopadhyay P, Sharma AK, Ram V (2013) Development of solid lipid nanoparticles of lopinavir using hot self nano-emulsification (SNE) technique. Eur J Pharm Sci 48:231–239.  https://doi.org/10.1016/j.ejps.2012.10.02CrossRefPubMedGoogle Scholar
  93. Nicky L, Conrad M, Kabanda T (2008) Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in Southwestern Uganda. Clin Infect Dis 47:1556–1561.  https://doi.org/10.1086/593194CrossRefGoogle Scholar
  94. Olbrich C, Gessner A, Kayser O, Muller RH (2002) Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic anti trypanosomal drug diminazene diaceturate. J Drug Target 10:387–396.  https://doi.org/10.1080/1061186021000001832CrossRefPubMedGoogle Scholar
  95. Omwoyo WN, Ogutu B, Oloo F, Swai H, Kalombo L, Melariri P, Mahanga GM, Gathirwa JW (2014) Preparation, characterization, and optimization of primaquine-loaded solid lipid nanoparticles. Int J Nanomedicine 9:3865–3874.  https://doi.org/10.2147/IJN.S62630CrossRefPubMedPubMedCentralGoogle Scholar
  96. Pandita D, Ahuja A, Lather V, Dutta T, Velpandian T, Khar RK (2011) Development, characterization and in vitro assessement of stearylamine-based lipid nanoparticles of paclitaxel. Pharmazie 66:171–177.  https://doi.org/10.1691/ph.2011.0274CrossRefPubMedGoogle Scholar
  97. Pandya NT, Jani P, Vanza J, Tandel H (2018) Solid lipid nanoparticles as an efficient drug delivery system of olmesartan medoxomil for the treatment of hypertension. Colloids Surf B Biointerfaces 165:37–44.  https://doi.org/10.1016/j.colsurfb.2018.02.011CrossRefPubMedGoogle Scholar
  98. Patro NM, Devi K, Pai RS, Sarasija S (2013) Evaluation of bioavailability, efficacy, and safety profile of doxorubicin-loaded solid lipid nanoparticles. J Nanopart Res 15:12–11.  https://doi.org/10.1007/s11051-013-2124-1CrossRefGoogle Scholar
  99. Penumarthi A, Parashar D, Abraham AN (2017) Solid lipid nanoparticles mediate non viral delivery of plasmid DNA to dendritic cells. J Nanopart Res 19:1–10.  https://doi.org/10.1007/s11051-017-3902-yCrossRefGoogle Scholar
  100. Pooja D, Kulhari H, Kuncha M, Rachamalla SS, Adams DJ, Bansal V, Sistla R (2016) Improving efficacy, Oral bioavailability, and delivery of paclitaxel using protein-grafted solid lipid nanoparticles. Mol Pharm 13:3903–3912.  https://doi.org/10.1021/acs.molpharmaceut.6b00691CrossRefPubMedGoogle Scholar
  101. Priano L, Zara GP, El-Assawy N, Cattaldo S, Muntoni E, Milano E, Serpe L, Musicanti C, Pérot C, Gasco MR, Miscio G, Mauro A (2011) Baclofen-loaded solid lipid nanoparticles: preparation, electrophysiological assessment of efficacy, pharmacokinetic and tissue distribution in rats after intraperitoneal administration. Eur J Pharm Biopharm 79:135–141.  https://doi.org/10.1016/j.ejpb.2011.02.009CrossRefPubMedGoogle Scholar
  102. Rahiminejad A, Dinarvand R, Johari B, Nodooshan SJ, Rashti A, Rismani E, Mahdaviani P, Saltanatpour Z, Rahiminejad S, Raigani M, Khosravani M (2019) Preparation and investigation of indirubin-loaded solid lipid nanoparticles nanoparticles and their anti-cancer effects on human glioblastoma U87MG cells. Cell Biol Int 43:2–11.  https://doi.org/10.1002/cbin.11037CrossRefPubMedGoogle Scholar
  103. Ravi PR, Vats R, Dalal V, Murthy AN (2014) A hybrid design to optimize preparation of lopinavir loaded solid lipid nanoparticles and comparative pharmacokinetic evaluation with marketed lopinavir/ritonavir coformulation. J Pharm Pharmacol 66:912–926.  https://doi.org/10.1111/jphp.12217CrossRefPubMedGoogle Scholar
  104. Ren J, Zou M, Gao P, Wang Y, Cheng G (2013) Tissue distribution of borneol modified ganciclovir-loaded solid lipid nanoparticles in mice after intravenous administration. Eur J Pharm Biopharm 83:141–148.  https://doi.org/10.1016/j.ejpb.2012.10.018CrossRefPubMedGoogle Scholar
  105. Rostami E, Kashanian S, Azandaryani AH (2014) Preparation of solid lipid nanoparticles as drug carriers for levothyroxine sodium with in vitro drug delivery kinetic characterization. Mol Biol Rep 41:3521–3527.  https://doi.org/10.1007/s11033-014-3216-4CrossRefPubMedGoogle Scholar
  106. Shah R, Eldridge D, Palombo E, Harding I (2015) Lipid nanoparticles: production, characterization and stability. Springer Chem Heidelberg, New York/Dordrecht/London.  https://doi.org/10.1007/978-3-319-10711-0CrossRefGoogle Scholar
  107. Shegokar R, Singh KK, Müller RH (2011) Production & stability of stavudine solid lipid nanoparticles from lab scale to industrial scale. Int J Pharm 416:461–470.  https://doi.org/10.1016/j.ijpharm.2010.08.014CrossRefPubMedGoogle Scholar
  108. Shenoy VS, Vijay IK, Murthy RSR (2005) Tumour targeting: biological factors and formulation advances in injectable lipid nanoparticles. J Pharm Pharmacol 57:411–421.  https://doi.org/10.1211/0022357055894CrossRefPubMedGoogle Scholar
  109. Silva AC, González-Mira E, García ML, Egea MA, Fonseca J, Silva R (2011) Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles: high pressure homogenization versus ultrasound. Colloids Surf B Biointerfaces 86:158–165.  https://doi.org/10.1016/j.colsurfb.2011.03.035CrossRefPubMedGoogle Scholar
  110. Soares S, Fonte P, Costa A, Andrade J, Seabra V, Ferreira D, Reis S, Sarmento B (2013) Effect of freeze-drying, cryoprotectants and storage conditions on the stability of secondary structure of insulin-loaded solid lipid nanoparticles. Int J Pharm 456:370–381.  https://doi.org/10.1016/j.ijpharm.2013.08.076CrossRefPubMedGoogle Scholar
  111. Stella B, Peira E, Dianzani C, Gallarate M, Battaglia L, Gigliotti CL, Boggio E, Dianzani U, Dosio F (2018) Development and characterization of solid lipid nanoparticles loaded with a highly active doxorubicin derivative. Nanomaterials (Basel) 8:1–16.  https://doi.org/10.3390/nano8020110CrossRefGoogle Scholar
  112. Suter F, Schmid D, Wandrey F, Zülli F (2016) Heptapeptide-loaded solid lipid nanoparticles for cosmetic anti-aging applications. Eur J Pharm:304–309.  https://doi.org/10.1016/j.ejpb.2016.06.014CrossRefGoogle Scholar
  113. Talegaonkar S, Vyas SP (2005) Inverse targeting of diclofenac sodium to reticuloendothelial system-rich organs by sphere-in-oil-in-water (s/o/w) multiple emulsion containing poloxamer 403. J Drug Target 13:173–178.  https://doi.org/10.1080/10611860500065104CrossRefPubMedGoogle Scholar
  114. Tang HB, Inoue A, Oshita K (2005) Zaltoprofen inhibits bradykinin–induced responses by blocking the activation of second messenger signaling cascades in rat dorsal root ganglion cells. Neuropharmacology 48:1035–1042.  https://doi.org/10.1016/j.neuropharm.2005.01.011CrossRefPubMedGoogle Scholar
  115. Teskač K, Kristl J (2010) The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int J Pharm 390:61–69.  https://doi.org/10.1016/j.ijpharm.2009.10.011CrossRefPubMedGoogle Scholar
  116. Tokuyasu N, Shomori K, Amano K, Honjo S, Sakamoto T, Watanabe J, Amisaki M, Morimoto M, Uchinaka E, Yagyu T, Saito H, Ito H, Fujiwara Y (2018) Indirubin, a constituent of the Chinese herbal medicine Qing-Dai, attenuates dextran sulfate sodium-induced murine colitis. Yonago Acta Med 61:128–136CrossRefGoogle Scholar
  117. Vedagiri A, Thangarajan S (2016) Mitigating effect of chrysin loaded solid lipid nanoparticles against amyloid β25-35 induced oxidative stress in rat hippocampal region: an efficient formulation approach for Alzheimer’s disease. Neuropeptides 58:111–125.  https://doi.org/10.1016/j.npep.2016.03.002CrossRefPubMedGoogle Scholar
  118. Venishetty VK, Chede R, Komuravelli R, Adepu L, Sistla R, Diwan PV (2012) Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: a novel strategy to avoid intraduodenal administration. Colloids Surf B Biointerfaces 95:1–9.  https://doi.org/10.1016/j.colsurfb.2012.01.001CrossRefPubMedGoogle Scholar
  119. Venishetty VK, Komuravelli R, Kuncha M, Sistla R, Diwan PV (2013) Increased brain uptake of docetaxel and ketoconazole loaded folate-grafted solid lipid nanoparticles. Nanomedicine 9:111–121.  https://doi.org/10.1016/j.nano.2012.03.003CrossRefPubMedGoogle Scholar
  120. Venkateswarlu V, Manjunath K (2004) Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release 95:627–638.  https://doi.org/10.1016/j.jconrel.2004.01.005CrossRefPubMedGoogle Scholar
  121. Wang W, Zhang L, Chen T, Guo W, Bao X, Wang D, Ren B, Wang H, Li Y, Wang Y, Chen S, Tang B, Yang Q, Chen C (2017) Anticancer effects of resveratrol-loaded solid lipid nanoparticles on human breast cancer cells. Molecules (Basel, Switzerland) 22:1–11.  https://doi.org/10.3390/molecules22111814CrossRefGoogle Scholar
  122. Wang W, Chen T, Xu H, Ren B, Cheng X, Qi R, Liu H, Wang Y, Yan L, Chen S, Yang Q, Chen C (2018) Curcumin-loaded solid lipid nanoparticles enhanced anticancer efficiency in breast cancer. Molecules (Basel, Switzerland) 23:1–13.  https://doi.org/10.3390/molecules23071578CrossRefGoogle Scholar
  123. Weber S, Zimmer A, Pardeike J (2014) Solid lipid nanoparticles and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art. Eur J Pharm Biopharm 86:7–22.  https://doi.org/10.1016/j.ejpb.2013.08.013CrossRefPubMedGoogle Scholar
  124. Westesen K, Siekmann B (1996) Biodegradable colloidal drug carrier systems based on solid lipids. In: Benita S (ed) Microencapsulation methods and industrial applications. Marcel Dekkar, Inc, New York, pp 1–20Google Scholar
  125. Wissing SA, Mäder K, Müller RH (2000) Solid lipid nanoparticles (SLN) as a novel carrier system offereing prolonged release of perfume allure (Chanel). In: Int Symp Control Release Bioact Mater, pp 311–312Google Scholar
  126. Wissing SA, Muller RH (2001) Solid lipid nanoparticles –a novel carrier for UV blockers. Pharmazie 56:783–786PubMedGoogle Scholar
  127. Wissing SA, Kayser O, Müller RH (2004) Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56:1257–1272.  https://doi.org/10.1016/j.addr.2003.12.002CrossRefPubMedGoogle Scholar
  128. Wong HL, Rauth AM, Bendayan R, Wu XY (2006) Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment for multidrug-resistant breast cancer. J Control Release 116:275–284.  https://doi.org/10.1016/j.jconrel.2006.09.007CrossRefPubMedGoogle Scholar
  129. Xie S, Zhu L, Dong Z, Wang X, Wang Y, Li X, Zhou W (2011) Preparation, characterization and pharmacokinetics of enrofloxacin-loaded solid lipid nanoparticles: influences of fatty acids. Colloids Surf B Biointerfaces 83:382–387.  https://doi.org/10.1016/j.colsurfb.2010.12.014CrossRefPubMedGoogle Scholar
  130. Yang S, Zhu JB, Lu Y, Liang BW, Yang CZ (1999a) Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res 16:751–757.  https://doi.org/10.1023/A:1018888927852CrossRefPubMedGoogle Scholar
  131. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ (1999b) Body distribution in mice intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release 59:299–307.  https://doi.org/10.1016/S0168-3659(99)00007-3CrossRefPubMedGoogle Scholar
  132. Yang R, Gao RC, Cai CF, Xu H, Li F, He HB, Tang X (2010) Preparation of gel-core-solid lipid nanoparticle: a novel way to improve the encapsulation of protein and peptide. Chem Pharm Bull (Tokyo) 58:1195–1202.  https://doi.org/10.1248/cpb.58.1195CrossRefGoogle Scholar
  133. Yasir M, Sara US, Chauhan I, Gaur PK, Singh AP, Puri D, Zafar A (2018) Solid lipid nanoparticles for nose to brain delivery of donepezil: formulation, optimization by Box–Behnken design. Artif Cells, Nanomed, Biotechnol 46:1838–1851.  https://doi.org/10.1080/21691401.2017.1394872CrossRefGoogle Scholar
  134. Ying XY, Cui D, Yu L, Du YZ (2011) Solid lipid nanoparticles modified with chitosan oligosaccharides for the controlled release of doxorubicin. Carbohydr Polym 84:1357–1364.  https://doi.org/10.1016/j.carbpol.2011.01.037CrossRefGoogle Scholar
  135. Yu YH, Kim E, Park DE, Shim G, Lee S, Kim YB, Kim CW, Oh YK (2012) Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA. Eur J Pharm Biopharm 80:268–273.  https://doi.org/10.1016/j.ejpb.2011.11.002CrossRefPubMedGoogle Scholar
  136. Yusuf M, Khan M, Khan RA, Ahmed B (2013) Preparation, characterization, in vivo and biochemical evaluation of brain targeted Piperine solid lipid nanoparticles in an experimentally induced Alzheimer’s disease model. J Drug Target 21:300–311.  https://doi.org/10.3109/1061186X.2012.747529CrossRefPubMedGoogle Scholar
  137. Zara GP, Cavalli R, Fundarò A, Bargoni A, Caputo O, Gasco MR (1999) Pharmacokinetics of doxorubicin incorporated in solid lipid nanoparticles. Pharmacol Res 40:281–286.  https://doi.org/10.1006/phrs.1999.0509CrossRefPubMedGoogle Scholar
  138. Zariwala MG, Elsaid N, Jackson TL, Corral López F, Farnaud S, Somavarapu S, Renshaw D (2013) A novel approach to oral iron delivery using ferrous sulphate loaded solid lipid nanoparticles. Int J Pharm 18:400–407.  https://doi.org/10.1016/j.ijpharm.2013.08.070CrossRefGoogle Scholar
  139. Zhang N, Ping Q, Huang G, Xu W, Cheng Y, Han X (2006) Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int J Pharm 327:153–159.  https://doi.org/10.1016/j.ijpharm.2006.07.026CrossRefPubMedPubMedCentralGoogle Scholar
  140. Zhiyong X, Qiongfeng L, Xinjun X (2006) Rapid and sensitive determination of donepezil in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study. Rapid Commun Mass Spectrom 20:3193–3198.  https://doi.org/10.1002/rcm.2718CrossRefGoogle Scholar
  141. Zhou Y, Zhang G, Rao Z, Yang Y, Zhou Q, Qin H, Wei Y, Wu X (2015) Increased brain uptake of venlafaxine loaded solid lipid nanoparticles by overcoming the efflux function and expression of P-gp. Arch Pharm Res 38:1325–1335.  https://doi.org/10.1007/s12272-014-0539-6CrossRefPubMedGoogle Scholar
  142. Zimmemann E, Muller RH (2001) Electrolyte and pH-stabilities of aqueous solid lipid nanoparticle (solid lipid nanoparticlesTM) dispersions in artificial gastrointestinal media. Eur J Pharm Biopharm 52:203–210.  https://doi.org/10.1016/S0939-6411(01)00167-9CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Abhishek Pandey
    • 1
  1. 1.School of Studies in Pharmaceutical SciencesJiwaji UniversityGwaliorIndia

Personalised recommendations